A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

By W. Sandborn, B. Feagan, R. Fedorak, E. Scherl, M. Fleisher, S. Katz, J. Johanns, M. Blank, P. Rutgeerts. Gastroenterology, 2008

774 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Human inflammatory dendritic cells induce Th17 cell differentiation. (2013, background): “Moreover, treating patients with blocking antibodies against IL-23 has shown promising results in the treatment of psoriasis (Kimball et al., 2008; Krueger et al., 2007) and Crohn’s disease (Sandborn et al., 2008).”
Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Interestingly, more frequent dosing seems to be required for patients with Crohn's disease and may reflect differences in the biology of IL-12 and IL-23 in these two immunologically and genetically related disease”
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis (2010, positive): “Thus, ustekinumab was studied in a double-blind, cross-over trial of 104 patients with moderate-to-severe Crohn’s disease.(47) Patients were randomly assigned to one of four groups: 1) subcutaneous placebo weekly at weeks 0–3 then 90 mg at weeks 8–11; 2) subcutaneous 90 mg weekly at weeks 0-3 then p”